PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24613631-10	2014	CONCLUSIONS: The outcomes of the recent ADF labeling applications for OxyContin( ) (Tier 3 approval) and Opana( ) (non-approval) suggest that the threshold for ADF labeling will be appropriately high.	Oxycodone	70-79	destrin, actin depolymerizing factor	Homo sapiens	40-43	
30597739-6	2019	The approved ER/LA opioids with ADF labeling in the United States include formulations of oxycodone, hydrocodone, and morphine.	Oxycodone	90-99	destrin, actin depolymerizing factor	Homo sapiens	32-35	
28778859-2	2017	The development of abuse-deterrent formulations (ADFs) of conventional opioids such as oxycodone and morphine represents an advance in the field and has had a positive but insufficient impact, as most opioids are still prescribed in highly abusable, non-ADF forms, and abusers can tamper with ADF medications to liberate the abusable opioid within.	Oxycodone	87-96	destrin, actin depolymerizing factor	Homo sapiens	49-52	
24613631-10	2014	CONCLUSIONS: The outcomes of the recent ADF labeling applications for OxyContin( ) (Tier 3 approval) and Opana( ) (non-approval) suggest that the threshold for ADF labeling will be appropriately high.	Oxycodone	70-79	destrin, actin depolymerizing factor	Homo sapiens	160-163